Navigation Links
Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol

SCOTTSDALE, Ariz., Feb. 6 /PRNewswire/ -- Cancer Clinics of Excellence, LLC, the nation's only physician-driven network of community oncologists, announced the completion of its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 of the leading oncology disease states at the 4th Annual Community Oncology Conference today. "Our 200+ member national oncology group is now fully prepared to launch the protocols across its network in 16 States," announced Frederick M. Schnell, MD, Central Georgia Cancer Care, Macon, GA, and CCE's Chief Clinical Officer.


"CCE's proprietary Evidence-based Treatment Protocols represent a significant advantage for community oncology practices around the country as they assimilate a vast amount of information into a usable clinical outcome tool. By integrating the protocols into the member oncology practices, physicians will be able to demonstrate to consumers the value of practicing evidence-based medicine across the entire continuum of care in oncology," stated Dr. Schnell. "The sheer breadth of these protocols is testament to the diligence of our 11 national physician User Groups and the cohesiveness of the network. With the release of our 62nd protocol, our broad network of community oncologists utilizes empirical, evidence-based and referenced protocols in treating our patients. This assures that we remain focused on value based medicine while using the most current evidence to treat our patients," added Arthur "Chip" Staddon, MD, Pennsylvania Oncology, Philadelphia, PA, Chairman of CCE.

"CCE provides its growing membership of physicians with a robust set of tools and resources including an integrated information technology platform, proprietary Evidence-based Treatment Protocols, and a collaborative model of care planning and management that are necessary to demonstrate clinical efficiency and outcomes," stated J. Ike Nicoll, CEO of CCE. "Given the current challenges in the healthcare market, CCE's approach will have a meaningful effect on improved clinical quality and economic outcome as our member practices collectively treat over 150,000 cancer patients annually. Therefore our commitment to evidence-based medicine is consistent with the country's need to raise the standards of quality while keeping healthcare affordable," added Mr. Nicoll.

The Co-Chairs of the 4th Annual Community Oncology Conference, CCE's Chief Medical Officer, Linda Bosserman, MD, of Wilshire Oncology Medical Group in Southern California and David Henry, MD, of Pennsylvania Oncology, in Philadelphia opened the meeting. Also speaking were CCE members, Patrick Cobb, MD, Hematology Oncology Centers of the Northern Rockies, Billings, MT and President of the Community Oncology Alliance, and Kent Butcher, CEO of Oklahoma Oncology, Tulsa, OK.

About Cancer Clinics of Excellence, LLC

Cancer Clinics of Excellence is the nations only practice-owned and physician driven network that empowers oncologists to deliver proven, evidence-based treatment in community settings while ensuring the performance of their practices. For more information, visit us at

SOURCE Cancer Clinics of Excellence, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
(Date:11/24/2015)...  Twist Bioscience, a company focused on synthetic ... Bioscience chief executive officer, will present at the ... 2015 at 3:10 p.m. Eastern Time at The Lotte New ... --> --> About Twist ... on Twitter. Sign up to follow our Twitter ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):